Brady L Stein
Overview
Explore the profile of Brady L Stein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
964
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gerds A, Mesa R, Burke J, Grunwald M, Stein B, Squier P, et al.
Blood
. 2023 Dec;
143(16):1646-1655.
PMID: 38142448
Polycythemia vera (PV) is a myeloproliferative neoplasm characterized by clonal proliferation of hematopoietic progenitor cells and is associated with an increased risk of thrombotic events (TEs). Established risk factors for...
2.
Odetola O, Martin K, Dreyer M, Rajan P, Zakarija A, Stein B
Br J Haematol
. 2023 May;
202(4):879-882.
PMID: 37226361
Thrombotic thrombocytopenic purpura (TTP) is not uncommonly seen in pregnancy, either with the first episode or with the exacerbation of known disease. The management of TTP in pregnancy can be...
3.
Stein B
Leuk Lymphoma
. 2022 Oct;
64(2):292-299.
PMID: 36301740
The management of myelofibrosis has improved following approval of the JAK1/JAK2 inhibitor, ruxolitinib. This agent laid the foundation for JAK inhibitor therapy, yet limitations have included myelosuppression and other adverse...
4.
Gerds A, Gotlib J, Ali H, Bose P, Dunbar A, Elshoury A, et al.
J Natl Compr Canc Netw
. 2022 Sep;
20(9):1033-1062.
PMID: 36075392
The classic Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) consist of myelofibrosis, polycythemia vera, and essential thrombocythemia and are a heterogeneous group of clonal blood disorders characterized by an overproduction of blood...
5.
Stein B
Curr Hematol Malig Rep
. 2021 Sep;
16(5):483-489.
PMID: 34499329
Purpose Of Review: The management of myelofibrosis is risk-adapted when considering transplant eligibility and symptom-directed, prioritizing the most burdensome symptoms for the patient. Unfortunately, myelofibrosis-anemia is common, multifactorial in its...
6.
Kudlaty E, Perez M, Stein B, Bochner B, Kuang F
J Allergy Clin Immunol Pract
. 2021 Mar;
9(6):2534-2536.
PMID: 33677080
No abstract available.
7.
Gerds A, Gotlib J, Bose P, Deininger M, Dunbar A, Elshoury A, et al.
J Natl Compr Canc Netw
. 2020 Sep;
18(9):1248-1269.
PMID: 32886902
Eosinophilic disorders and related syndromes represent a heterogeneous group of neoplastic and nonneoplastic conditions, characterized by more eosinophils in the peripheral blood, and may involve eosinophil-induced organ damage. In the...
8.
Galvez C, Stein B
Curr Hematol Malig Rep
. 2020 May;
15(4):261-267.
PMID: 32399765
Purpose Of Review: Thrombocytosis is common to all myeloproliferative neoplasms (MPN), including essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis. Despite the traditionally held belief amongst many clinicians that thrombocytosis...
9.
Lin C, Martin K, Wang M, Stein B, Desai K
Phlebology
. 2019 Dec;
35(6):402-408.
PMID: 31821779
Objectives: To examine the prescribing patterns and outcomes of antithrombotic regimens after venous stent placement. Methods: A total of 87 patients who received inferior vena cava or iliofemoral venous stents...
10.
Stein B, Martin K
Hematology Am Soc Hematol Educ Program
. 2019 Dec;
2019(1):397-406.
PMID: 31808903
Thrombotic and hemorrhagic complications are prevalent in patients with essential thrombocythemia, polycythemia vera, and myelofibrosis. Given the impact on morbidity and mortality, reducing the risk of thrombosis and/or hemorrhage is...